Hallmarks of Resistance to Immune-Checkpoint Inhibitors.

ABSTRACT: Immune-checkpoint inhibitors (ICI), although revolutionary in improving long-term survival outcomes, are mostly effective in patients with immune-responsive tumors. Most patients with cancer either do not respond to ICIs at all or experience disease progression after an initial period of response. Treatment resistance to ICIs remains a major challenge and defines the biggest unmet medical need in oncology worldwide. In a collaborative workshop, thought leaders from academic, biopharma, and nonprofit sectors convened to outline a resistance framework to support and guide future immune-resistance research. Here, we explore the initial part of our effort by collating seminal discoveries through the lens of known biological processes. We highlight eight biological processes and refer to them a

SUBMITTER: Karasarides M 

PROVIDER: S-EPMC9381103 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature